CL2021002152A1 - Métodos para tratar el dolor de la superficie ocular - Google Patents

Métodos para tratar el dolor de la superficie ocular

Info

Publication number
CL2021002152A1
CL2021002152A1 CL2021002152A CL2021002152A CL2021002152A1 CL 2021002152 A1 CL2021002152 A1 CL 2021002152A1 CL 2021002152 A CL2021002152 A CL 2021002152A CL 2021002152 A CL2021002152 A CL 2021002152A CL 2021002152 A1 CL2021002152 A1 CL 2021002152A1
Authority
CL
Chile
Prior art keywords
ocular surface
methods
treating ocular
surface pain
treating
Prior art date
Application number
CL2021002152A
Other languages
English (en)
Inventor
Quintus Medley
Muneto Mogi
Michela Montecchi-Palmer
Kalliopi Stasi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021002152A1 publication Critical patent/CL2021002152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para tratar el dolor de la superficie ocular mediante la administración de 4-(7-hidroxi-2-isopropil-4-oxo-4H-quinazolin-3-il)-benzonitrilo (compuesto I). La presente invención además proporciona métodos para tratar la enfermedad del ojo seco y la hiperemia ocular mediante la administración de 4-(7-hidroxi-2-isopropil-4-oxo-4H-quinazolin-3-il)-benzonitrilo.
CL2021002152A 2019-02-15 2021-08-13 Métodos para tratar el dolor de la superficie ocular CL2021002152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
CL2021002152A1 true CL2021002152A1 (es) 2022-04-18

Family

ID=69740423

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002152A CL2021002152A1 (es) 2019-02-15 2021-08-13 Métodos para tratar el dolor de la superficie ocular

Country Status (15)

Country Link
US (3) US20200261456A1 (es)
EP (1) EP3923909A1 (es)
JP (1) JP2022520832A (es)
KR (1) KR20210129677A (es)
CN (1) CN113453686A (es)
AU (2) AU2020222348B2 (es)
BR (1) BR112021015998A2 (es)
CA (1) CA3130038A1 (es)
CL (1) CL2021002152A1 (es)
IL (1) IL284629A (es)
JO (1) JOP20210217A1 (es)
MX (1) MX2021009702A (es)
SG (1) SG11202107260VA (es)
TW (1) TW202045179A (es)
WO (1) WO2020165838A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AU2006311883A1 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
KR20100039410A (ko) 2007-07-18 2010-04-15 노파르티스 아게 Ｖｒ－１ 길항제 및 ｃｏｘ－２ 억제제의 상승적 조합물
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
JP2011509296A (ja) 2008-01-09 2011-03-24 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体およびそれを使用する薬学的組成物および方法
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
US8394779B2 (en) 2008-06-04 2013-03-12 Children's Medical Center Corporation Methods of modulating angiogenesis via TRPV4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP3515888B1 (en) 2016-09-20 2021-03-31 GlaxoSmithKline Intellectual Property (No. 2) Limited Trpv4 antagonists
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤

Also Published As

Publication number Publication date
AU2020222348A1 (en) 2021-08-05
CA3130038A1 (en) 2020-08-20
BR112021015998A2 (pt) 2021-10-05
US20210275529A1 (en) 2021-09-09
AU2020222348B2 (en) 2023-03-16
CN113453686A (zh) 2021-09-28
IL284629A (en) 2021-08-31
JOP20210217A1 (ar) 2023-01-30
AU2023203716A1 (en) 2023-07-06
US20200261456A1 (en) 2020-08-20
WO2020165838A9 (en) 2021-03-18
EP3923909A1 (en) 2021-12-22
TW202045179A (zh) 2020-12-16
JP2022520832A (ja) 2022-04-01
WO2020165838A1 (en) 2020-08-20
KR20210129677A (ko) 2021-10-28
US20220193078A1 (en) 2022-06-23
US11234982B2 (en) 2022-02-01
SG11202107260VA (en) 2021-08-30
MX2021009702A (es) 2021-09-14

Similar Documents

Publication Publication Date Title
CO2021010689A2 (es) Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo
CU20200014A7 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
NI202100029A (es) 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav 1.8
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
CO2020005459A2 (es) Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
EA202191519A1 (ru) Модуляторы trex1
EA202190395A1 (ru) Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
UY36716A (es) Moduladores de receptores nucleares
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
CL2020001183A1 (es) Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.
EA202092719A1 (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
EA202190576A1 (ru) Полиморфные соединения и их применение
CL2019002583A1 (es) Inhibidores duales de magl y faah.
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
CL2021002152A1 (es) Métodos para tratar el dolor de la superficie ocular
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
ECSP22001774A (es) Composiciones para el tratamiento de la pérdida del cabello
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering